Friday, April 03, 2020 6:08:36 AM
Lemmiwinks please read below. Hydroxychloroquine (HCQ) has been obscenely politicized by both sides. Like Vascepa, you need to understand the basic science that explains its in vitro antiviral effect. Without getting into details, I have been in this since February. Follow what I am suggesting, it may save your life, it might have saved mine. As long as you don't have a baseline cardiac arrhythmia you will be fine. Dr. Howard Zucker is the Commissioner of the Dept of Health NYS:
Dear Dr. Zucker,
My name is xxxxxxxx, and I am a retina surgeon in the Hudson Valley who the New York Times recently put in touch with Gary Holmes regarding the use of Hydroxychloroquine to treat COVID-19. I wanted to be sure to write you directly about a critical aspect of our findings: Hydroxychloroquine is an effective treatment for COVID-19, but only if administered early enough and at a significantly high loading dose. (This is based on my analysis of worldwide case data and personal clinical experience).
I hope you will consider evaluating the protocol below, which I believe would substantially reduce the number of New Yorkers needing hospitalization and critical care for COVID-19, and also add a layer of protection for HCPs:
Protocol
1) Maintain frontline medical personal on 400mg QD of Hydroxychloroquine. This is a routine Lupus/RA dose and will have minimal side effects. It will create a steady drug level in the lungs that probably reaches EC 50 for SARS-CoV-2.
2) If clinical signs of COVID-19 present the following is done, administer the drug as follows: Day 1-3 800mg QD (EC 90 Levels); Day 4-6 600mg/QD; Day 7-10 400mg/QD, optimally with testing done in the first week. This dosing also addresses potential side-effects specifically Q-T prolongation. I can say with certainty that retinopathy is a total nonissue.
Administering HCQ in the early stages of COVID-19 is essential. Like Tamiflu, HCQ’s clinical efficacy will be maximized early in COVID-19. There is a window of maximum effect. Endstage/ICU patients are likely in the throws of cytokine storm. At that point HCQ (or even Remdesivir) will be minimally effective, and could even be deleterious due to the amplification of side effects as organs begin to fail.
Based on PCR data from now several independent international studies, which I would be happy to detail further, this protocol should eradicate COVID-19 within a week among many patients. This would have a profoundly positive effect on community transmission and hospital overflow in New York.
I am eager to discuss further and can be reached at any time at xxxxxxxxxx.
Sincerely,
xxxxxxxxxxx, MD
Dear Dr. Zucker,
My name is xxxxxxxx, and I am a retina surgeon in the Hudson Valley who the New York Times recently put in touch with Gary Holmes regarding the use of Hydroxychloroquine to treat COVID-19. I wanted to be sure to write you directly about a critical aspect of our findings: Hydroxychloroquine is an effective treatment for COVID-19, but only if administered early enough and at a significantly high loading dose. (This is based on my analysis of worldwide case data and personal clinical experience).
I hope you will consider evaluating the protocol below, which I believe would substantially reduce the number of New Yorkers needing hospitalization and critical care for COVID-19, and also add a layer of protection for HCPs:
Protocol
1) Maintain frontline medical personal on 400mg QD of Hydroxychloroquine. This is a routine Lupus/RA dose and will have minimal side effects. It will create a steady drug level in the lungs that probably reaches EC 50 for SARS-CoV-2.
2) If clinical signs of COVID-19 present the following is done, administer the drug as follows: Day 1-3 800mg QD (EC 90 Levels); Day 4-6 600mg/QD; Day 7-10 400mg/QD, optimally with testing done in the first week. This dosing also addresses potential side-effects specifically Q-T prolongation. I can say with certainty that retinopathy is a total nonissue.
Administering HCQ in the early stages of COVID-19 is essential. Like Tamiflu, HCQ’s clinical efficacy will be maximized early in COVID-19. There is a window of maximum effect. Endstage/ICU patients are likely in the throws of cytokine storm. At that point HCQ (or even Remdesivir) will be minimally effective, and could even be deleterious due to the amplification of side effects as organs begin to fail.
Based on PCR data from now several independent international studies, which I would be happy to detail further, this protocol should eradicate COVID-19 within a week among many patients. This would have a profoundly positive effect on community transmission and hospital overflow in New York.
I am eager to discuss further and can be reached at any time at xxxxxxxxxx.
Sincerely,
xxxxxxxxxxx, MD
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
